Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02506023 · ClinicalTrials.gov registry record · Phase 1
Characterization of Laboratory Response to DDAVP in Adult Hemophilia A Carriers
A Phase 1 study of Hemophilia A, sponsored by Emory University.
- Completed
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
- 2
- Study locations
NCT02506023: Completed Phase 1 study of Hemophilia A, sponsored by Emory University.
NCT02506023 is a Phase 1 study of Hemophilia A that has completed, run by Emory University. The registered enrollment target is 2 participants, below the 92-participant average among 42 other Hemophilia A trials with a reported enrollment target (98% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02506023, a Phase 1 study of Hemophilia A, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to determine how female hemophilia A carriers respond to a medication called DDAVP (Desmopressin).
Primary Outcome
After administration of intravenous Desmopressin (DDAVP) at 0.3mcg/kg, the percentage of subjects that achieve and sustain Factor VIII antigen (FVIII:C) levels \>50% at 240 minutes as compared to baseline will be recorded. The levels of Factor VIII antigen (FVIII:C) will be measured using a one-stage assay. The laboratory response between carriers and the control group will be compared and the percentage of subjects that have greater than a 2-fold response from baseline and sustainment of Factor
Conditions Studied
Interventions
- DRUG Desmopressin
Study Locations (2)
Georgia
- Children's Hospital of Atlanta Egleston - Atlanta
- Emory University - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2015-07 |
| Est. Completion | 2018-06-15 |
| Phase | Phase 1 |
What the finished NCT02506023 record still lists
NCT02506023 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 92-participant average among 42 other Hemophilia A trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Hemophilia A appearing as the primary indexed condition, and to 1 intervention - of which Desmopressin is the first listed.
NCT02506023 reports a single indexed study location in Georgia.
Frequently Asked Questions
What is clinical trial NCT02506023 about?
NCT02506023 is a clinical study titled "Characterization of Laboratory Response to DDAVP in Adult Hemophilia A Carriers". The purpose of this study is to determine how female hemophilia A carriers respond to a medication called DDAVP (Desmopressin).
What is the current status of trial NCT02506023?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2015-07. Estimated completion is 2018-06-15.
What conditions does trial NCT02506023 study?
This clinical trial studies the following conditions: Hemophilia A.
What interventions are being tested in trial NCT02506023?
The interventions under investigation include: Desmopressin (DRUG).
Who is sponsoring clinical trial NCT02506023?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02506023 being conducted?
This trial has 2 study locations across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hemophilia A
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02506023's enrollment target sits among peer trials
2 43rd of 42 the lowest of 42 other Hemophilia A trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hemophilia A trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Gene Therapy Study of SPK-8011QQ in Adults With Severe or Moderately Severe Hemophilia A
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With Severe or Moderate Hemophilia A
RECRUITING · Phase 1
-
ASC618 Gene Therapy in Hemophilia A Patients
RECRUITING · Phase 1
-
A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Two Participants Groups (Part A: Healthy Participants, and Part B: Participants With Hemophilia A or Hemophilia B or Factor VII Deficiency)
RECRUITING · Phase 1
-
Gene Therapy Trial for Platelet Derived Factor VIII Production in Hemophilia A
ACTIVE NOT RECRUITING · Phase 1
-
Gene Therapy for Haemophilia A.
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia